Arkolith/Insider Trading/APRE/Form 4

Gilad Oren

President/CEO, DirectorAprea Therapeutics, Inc. (APRE) · full profile →Form 4 · filed Apr 4, 2025
Net Buying
Open-Market Buys
$10K
Open-Market Sells
$0
Net Open-Market Flow
$10K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 3, 2025Buy(P)2K$1.80$4K346K
Apr 3, 2025Buy(P)3K$1.87$6K343K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-031991) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML